新型抗肿瘤药物不良反应分析及药学监护

Analysis of adverse reactions of novel anti-tumor drugs and pharmaceutical care

随着对肿瘤研究的不断深入,新型抗肿瘤药物在临床中得到了广泛应用,展现了良好的临床治疗价值,但其所诱发的免疫相关不良反应(ADR)、脏器损伤等也引发了越来越多的关注。本文围绕实体肿瘤和血液肿瘤最新诊疗指南中推荐的新型抗肿瘤药物,以药理学作用机制为脉络,对同类药物所致共性ADR及上市后新的/严重ADR进行综述,并阐述了药学监护要点与模式,以期为该类药物的研究、临床治疗以及合理用药提供借鉴。

With the deepening research,novel anti-tumor drugs have been widely used,showing good clinical therapeutic value,but the immune-related adverse reactions and organ damage caused have also attracted more and more attention.Focus on the novel anti-tumor drugs recommended in the latest diagnosis and treatment guidelines for solid and hematologic tumors,according to the classification by pharmacological mechanisms,this review is proposed to summarize common adverse reactions caused by the drugs and the new/serious adverse reactions reported.The key points and models of pharmaceutical care are also described in detail,to provide reference for the research,clinical treatment and reasonable medication of the novel anti-tumor drugs.